2016 Fiscal Year Final Research Report
Tumoral immune escape mechanism in malignant glioma
| Project/Area Number |
26870237
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Immunology
Neurosurgery
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | グリオーマ / 免疫療法 / トリプトファン / キヌレニン / インドールアミン2，3ジオキシゲナーゼ |
|---|
| Outline of Final Research Achievements |
Indoleamine 2,3-dioxygenase (IDO), a key enzyme of tryptophan (Trp) metabolism, is involved in tumor-derived immune suppression by depleting Trp and accumulating the metabolite. We have recently shown that IDO expression was markedly increased in human glioblastoma and secondary glioblastoma with malignant change. The aim of this study is to investigate anti-tumor effect of IDO inhibition and to search the synergistic function of IDO inhibitor (1-MT) and temozolomide in a murine glioma model. In subcutaneous model, oral administration of 1-MT significantly suppressed tumor growth and synergistic anti-tumor effects of 1-MT and temozolomide were observed (P<0.01). The mice intracranially inoculated IDO knockdown cells had a significantly longer survival compared to the control mice (P<0.01). The mice intracranially inoculated IDO knockdown cells had a significantly longer survival compared to the control mice (P<0.01).
|
| Free Research Field |
悪性脳腫瘍
|
